+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bleeding Disorders Treatment Market - Global Forecast to 2030- Product Image
Bleeding Disorders Treatment Market - Global Forecast to 2030- Product Image
Sale

Bleeding Disorders Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010944
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bleeding Disorders Treatment Market grew from USD 14.80 billion in 2024 to USD 16.24 billion in 2025. It is expected to continue growing at a CAGR of 9.32%, reaching USD 25.28 billion by 2030.

The bleeding disorders treatment landscape is undergoing a pivotal transformation driven by scientific breakthroughs, evolving patient expectations, and shifting healthcare policies. In recent years, innovations in coagulation factor therapies and novel modalities such as gene and cell therapies have redefined the standard of care. These advances not only promise enhanced efficacy and safety profiles but also aim to reduce the treatment burden through extended dosing intervals and non-factor options.

Healthcare stakeholders face mounting pressure to integrate these therapies within complex regulatory frameworks and reimbursement environments. As patients demand more personalized approaches, payers and providers must align on strategies that deliver value without compromising access. This introduction sets the stage for a comprehensive examination of the dynamic forces shaping bleeding disorders treatment, highlighting key shifts, tariff implications, segmentation nuances, regional variations, and competitive maneuvers that collectively influence decision-making for industry leaders and healthcare decision-makers alike.

Transformative Shifts Driving Innovation in Bleeding Disorders Care

Over the past decade, the bleeding disorders sector has witnessed transformative shifts driven by precision medicine and biotechnology advances. The emergence of bioengineered molecules and long-acting agents has extended therapeutic windows, enabling less frequent dosing and improved adherence. Simultaneously, non-factor products are offering alternative mechanisms to manage bleeding episodes, reducing reliance on traditional factor replacement.

At the same time, gene therapy has progressed from early clinical trials to real-world implementation, presenting the potential for durable, one-time interventions that can significantly improve quality of life. Transitional strategies blending prophylaxis with on-demand treatments are becoming mainstream, addressing both acute bleeding episodes and long-term prevention through primary and secondary prophylaxis. These innovations are accompanied by regulatory accelerations and heightened investment in monoclonal antibodies and cell therapy platforms, signaling an industry pivot toward curative and semi-curative solutions.

Consequently, the playing field is shifting from incremental improvements to paradigm-altering breakthroughs, requiring stakeholders to reassess strategic priorities and resource allocation.

Assessing the Cumulative Impact of 2025 US Tariffs on Treatment Accessibility

The introduction of new tariffs by the United States in 2025 has created ripple effects across global supply chains and pricing structures. Imported active pharmaceutical ingredients and specialized biologics now face higher duty burdens, compelling manufacturers to reevaluate sourcing strategies. Many players have shifted production closer to end markets or inked local manufacturing partnerships to mitigate cost pressures and ensure continuity of supply.

These adjustments have prompted some firms to absorb duties temporarily, maintaining patient access during negotiation periods, while others have restructured commercial models to recoup incremental costs through value-based contracts. Payers, in turn, are increasingly demanding real-world evidence to justify higher price points. As a result, companies are accelerating outcomes studies and leveraging patient registries to demonstrate long-term benefits, thereby reinforcing their negotiating position and safeguarding reimbursement pathways.

The cumulative impact of these tariffs extends beyond immediate cost implications, compelling a systemic shift toward more resilient, geographically diversified supply networks and reinforcing the importance of strategic agility.

Comprehensive Segmentation Insights Revealing Market Dynamics

A granular view of the bleeding disorders treatment market emerges when analyzed through multiple segmentation lenses. Based on treatment type, therapy options range from antifibrinolytic agents and desmopressin injection to plasma-derived and recombinant coagulation factor concentrates, each addressing distinct clinical needs. Patient demographics further refine these insights, distinguishing between adults, children, and elderly patients while accounting for gender-specific considerations that influence dosing and safety profiles.

Exploring therapeutic approach reveals two principal pathways: on-demand treatment for acute bleeding episodes or post-surgical hemorrhage, and prophylaxis treatment subdivided into primary and secondary strategies aimed at preventing spontaneous bleeds. Route of administration also plays a critical role; intravenous infusions dominate hospital and clinic settings, whereas oral and subcutaneous options facilitate home care administration, enhancing convenience and adherence.

End-user analysis highlights the evolving roles of home care settings versus hospitals, specialty care centers, and research institutes in driving protocol standardization and patient education. Underlying these categories, advances in cell therapy, gene therapy, and monoclonal antibodies are reshaping technology adoption curves. Innovations in bioengineered molecules, long-acting agents, and non-factor products exemplify therapeutic innovation, while disease-type segmentation-covering Hemophilia A, Hemophilia B, rare bleeding disorders, and Von Willebrand Disease-enables targeted product development. Finally, insurance coverage models, from charitable support programs and out-of-pocket payments to private insurance and public programs, determine patient access pathways and co-pay structures.

Regional Insights Highlighting Market Variations Across Key Geographies

Regional dynamics in bleeding disorders treatment reveal distinct drivers and challenges across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust private insurance markets coexist with government-funded programs, fostering rapid uptake of innovative gene and cell therapies. Meanwhile, Europe, the Middle East & Africa exhibit a mosaic of regulatory environments; established markets follow centralized pricing and reimbursement frameworks, whereas emerging economies wrestle with infrastructure constraints and variable patient awareness.

Asia-Pacific stands out for its combination of large patient populations and evolving healthcare systems. Countries such as Japan and South Korea lead in biotech adoption, while nations in Southeast Asia focus on building local manufacturing capabilities and strengthening public-private partnerships to expand access. Across all regions, digital health initiatives and telemedicine platforms are enhancing patient monitoring, enabling decentralized clinical trials, and driving data-driven reimbursement strategies. These regional variations underscore the need for tailored market entry and commercialization plans that align with local regulatory landscapes and payer expectations.

Key Company Strategies Shaping the Future of Bleeding Disorders Therapy

A competitive analysis of leading firms in the bleeding disorders arena illustrates diverse strategic approaches. Alnylam Pharmaceuticals and Amgen prioritize RNA-interference platforms and antibody-based therapies, respectively, to address unmet needs in Hemophilia A and B. Baxter International and Bayer AG leverage their legacy in plasma-derived concentrates while expanding portfolios into recombinant and long-acting factor products.

Biogen and Bristol-Myers Squibb invest heavily in non-factor and gene therapy research, partnering with academic institutions to accelerate translational pipelines. CSL Behring and Grifols focus on global network expansion, optimizing plasma collection systems and enhancing specialty care center collaborations. Meanwhile, Emergent BioSolutions, Kedrion, Novo Nordisk, Octapharma, Pfizer, and Sanofi maintain balanced portfolios that span conventional factor replacement to next-generation modalities, each differentiating through targeted clinical trials and real-world evidence generation.

Smaller innovators such as Xenetic Biosciences are carving niches in extracellular matrix technologies and immunomodulatory strategies, demonstrating that nimble biotechs can influence broader therapeutic paradigms.

Actionable Recommendations for Industry Leaders to Navigate Change

Industry leaders should prioritize three strategic imperatives. First, enhance patient-centric value propositions by integrating digital health tools and remote monitoring solutions into treatment programs, thereby improving adherence and outcomes. Second, forge strategic alliances that localize production and distribution, reducing exposure to tariff volatility and supply chain disruptions. Third, invest in robust real-world evidence generation to support value-based contracting and secure favorable formulary placements.

Additionally, companies must adopt agile regulatory strategies, submitting data for accelerated pathways and engaging with health authorities early to clarify evidentiary requirements. Emphasizing personalized medicine through biomarker development and companion diagnostics will further differentiate product offerings. Finally, aligning corporate social responsibility initiatives with charitable support programs and public coverage expansion can bolster reputation and broaden patient access, reinforcing long-term commercial viability.

Conclusion: Steadying the Course in a Dynamic Treatment Environment

The bleeding disorders treatment market stands at a crossroads, characterized by unprecedented innovation and complex external pressures. By synthesizing insights from market segmentation, regional dynamics, tariff impacts, and competitive strategies, stakeholders can chart a path that balances innovation with affordability and accessibility. Proactive collaboration among manufacturers, payers, providers, and patient advocacy groups will be essential in translating scientific breakthroughs into sustainable therapies that improve patient lives worldwide.

As the industry evolves, maintaining a patient-first mindset and leveraging data-driven decision-making will ensure that each advancement translates into tangible clinical benefits. Through strategic agility and focused investments, the sector can fulfill its promise of transforming bleeding disorder care into a more effective, personalized, and accessible reality.

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Antifibrinolytic Agents
  • Desmopressin Injection
  • Plasma-Derived Coagulation Factor Concentrates
  • Recombinant Coagulation Factor Concentrates
  • Age
    • Adults
    • Children
    • Elderly
  • Gender
  • On-Demand Treatment
    • Acute Bleeding Episodes
    • After Injury or Surgery
  • Prophylaxis Treatment
    • Primary Prophylaxis
    • Secondary Prophylaxis
  • Intravenous
  • Oral
  • Subcutaneous
  • Home Care Settings
  • Hospitals & Clinics
  • Research Institutes
  • Specialty Care Centers
  • Cell Therapy
  • Gene Therapy
  • Monoclonal Antibodies
  • Bioengineered Molecules
  • Long-Acting Agents
  • Non-Factor Products
  • Hemophilia A
  • Hemophilia B
  • Rare Bleeding Disorders
  • Von Willebrand Disease
  • Charitable Support Programs
  • Out-Of-Pocket Payments
  • Private Insurance
  • Public Programs

This research report categorizes the Bleeding Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bleeding Disorders Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols International, S.A.
  • Kedrion S.p.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Xenetic Biosciences, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bleeding Disorders Treatment Market, by Treatment Type
8.1. Introduction
8.2. Antifibrinolytic Agents
8.3. Desmopressin Injection
8.4. Plasma-Derived Coagulation Factor Concentrates
8.5. Recombinant Coagulation Factor Concentrates
9. Bleeding Disorders Treatment Market, by Patient Demographics
9.1. Introduction
9.2. Age
9.2.1. Adults
9.2.2. Children
9.2.3. Elderly
9.3. Gender
10. Bleeding Disorders Treatment Market, by Therapeutic Approach
10.1. Introduction
10.2. On-Demand Treatment
10.2.1. Acute Bleeding Episodes
10.2.2. After Injury or Surgery
10.3. Prophylaxis Treatment
10.3.1. Primary Prophylaxis
10.3.2. Secondary Prophylaxis
11. Bleeding Disorders Treatment Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Bleeding Disorders Treatment Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals & Clinics
12.4. Research Institutes
12.5. Specialty Care Centers
13. Bleeding Disorders Treatment Market, by Technology
13.1. Introduction
13.2. Cell Therapy
13.3. Gene Therapy
13.4. Monoclonal Antibodies
14. Bleeding Disorders Treatment Market, by Therapeutic Innovation
14.1. Introduction
14.2. Bioengineered Molecules
14.3. Long-Acting Agents
14.4. Non-Factor Products
15. Bleeding Disorders Treatment Market, by Disease Type
15.1. Introduction
15.2. Hemophilia A
15.3. Hemophilia B
15.4. Rare Bleeding Disorders
15.5. Von Willebrand Disease
16. Bleeding Disorders Treatment Market, by Insurance Coverage
16.1. Introduction
16.2. Charitable Support Programs
16.3. Out-Of-Pocket Payments
16.4. Private Insurance
16.5. Public Programs
17. Americas Bleeding Disorders Treatment Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Bleeding Disorders Treatment Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Bleeding Disorders Treatment Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Alnylam Pharmaceuticals Inc.
20.3.2. Amgen Inc.
20.3.3. Baxter International Inc.
20.3.4. Bayer AG
20.3.5. Biogen Inc.
20.3.6. Bristol-Myers Squibb Company
20.3.7. CSL Behring
20.3.8. Emergent BioSolutions Inc.
20.3.9. Grifols International, S.A.
20.3.10. Kedrion S.p.A.
20.3.11. Novo Nordisk A/S
20.3.12. Octapharma AG
20.3.13. Pfizer Inc.
20.3.14. Sanofi S.A.
20.3.15. Xenetic Biosciences, Inc.
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. BLEEDING DISORDERS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. BLEEDING DISORDERS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. BLEEDING DISORDERS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. BLEEDING DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. BLEEDING DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLEEDING DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ANTIFIBRINOLYTIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DESMOPRESSIN INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PLASMA-DERIVED COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RECOMBINANT COAGULATION FACTOR CONCENTRATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ACUTE BLEEDING EPISODES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AFTER INJURY OR SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRIMARY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SECONDARY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY BIOENGINEERED MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY LONG-ACTING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY NON-FACTOR PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY RARE BLEEDING DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY CHARITABLE SUPPORT PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY OUT-OF-POCKET PAYMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PUBLIC PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 91. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 94. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 95. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 101. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 102. CANADA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 127. UNITED STATES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 140. ASIA-PACIFIC BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 151. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 153. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 155. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 156. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 157. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 159. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 163. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 164. CHINA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 165. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 166. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 167. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 168. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 169. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 170. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 175. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 176. INDIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 187. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 188. INDONESIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 189. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 191. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 192. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 193. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 194. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 199. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 200. JAPAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 211. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 212. MALAYSIA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 223. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 224. PHILIPPINES BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 235. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 236. SINGAPORE BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 259. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. TAIWAN BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 261. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 262. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 263. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 264. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 265. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 266. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 271. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. THAILAND BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC INNOVATION, 2018-2030 (USD MILLION)
TABLE 295. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 296. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 297. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 298. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 299. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 300. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY AGE, 2018-2030 (USD MILLION)
TABLE 301. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2030 (USD MILLION)
TABLE 302. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY ON-DEMAND TREATMENT, 2018-2030 (USD MILLION)
TABLE 303. DENMARK BLEEDING DISORDERS TREATMENT MARKET SIZE, BY PROPHYLAXIS TREATMENT, 2018-2030 (USD MILLION)
TABLE 304. DEN

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • CSL Behring
  • Emergent BioSolutions Inc.
  • Grifols International, S.A.
  • Kedrion S.p.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Xenetic Biosciences, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032 - Product Image

Bleeding Disorders Treatment Market Report by Type, Drug Class, Distribution Channel, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Bleeding Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Bleeding Disorders Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
Uncontrolled Bleeding - Pipeline Insight, 2025 - Product Image

Uncontrolled Bleeding - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Coagulants Market Size, Share & Trends Analysis Report By Product (Systemic, Topical, Hemostatics), By Application (Surgeries, Trauma, Hemophilia, Bleeding), By Route Of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 150 Pages
  • Global
From
Next-Generation Therapeutics For Bleeding Disorders - Pipeline Insight, 2025 - Product Image

Next-Generation Therapeutics For Bleeding Disorders - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Bleeding Disorder Drug Market

The Bleeding Disorder Drug market is a subset of the Cardiovascular Drugs market, focusing on drugs used to treat bleeding disorders. These drugs are used to treat conditions such as hemophilia, von Willebrand disease, and other rare bleeding disorders. Bleeding Disorder Drugs are typically administered intravenously, and can be used to reduce the frequency of bleeding episodes, as well as to prevent and treat bleeding episodes. The Bleeding Disorder Drug market is highly competitive, with a number of companies offering products. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, Shire, and CSL Behring. Other companies in the market include Biogen, Grifols, Kedrion, Octapharma, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.